Latest Conference Articles

December 8th 2019, 2:48am

ASH Annual Meeting and Exposition

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

December 8th 2019, 1:46am

ASH Annual Meeting and Exposition

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

December 8th 2019, 1:33am

ASH Annual Meeting and Exposition

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

December 8th 2019, 12:51am

ASH Annual Meeting and Exposition

Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.

December 7th 2019, 11:50pm

ASH Annual Meeting and Exposition

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

December 7th 2019, 11:48pm

ASH Annual Meeting and Exposition

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

December 7th 2019, 10:48pm

ASH Annual Meeting and Exposition

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

December 7th 2019, 9:17pm

ASH Annual Meeting and Exposition

An investigational new drug application for the therapy, which is labeled FT596, was approved in September 2019 and human trials are scheduled to begin in the first quarter of 2020.

December 6th 2019, 7:44pm

ASH Annual Meeting and Exposition

Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.

December 4th 2019, 4:01am

State of the Science Summit on Genitourinary Cancers

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

December 4th 2019, 3:56am

State of the Science Summit on Genitourinary Cancers

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

November 27th 2019, 10:59pm

SMR Congress

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

November 26th 2019, 11:23pm

SMR Congress

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

November 26th 2019, 8:12pm

SMR Congress

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

November 26th 2019, 4:33am

State of the Science Summit on Genitourinary Cancers

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

November 25th 2019, 9:43pm

SMR Congress

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

November 24th 2019, 4:00pm

SMR Congress

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

November 24th 2019, 3:07am

SMR Congress

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

November 23rd 2019, 11:45pm

SMR Congress

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

November 23rd 2019, 8:05pm

SMR Congress

Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.